Pacira Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Earnings data Q1 2023

Earnings data Q2 2023

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

Why Is Pacira (PCRX) Down 6% Since Last Earnings Report?

The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks. A final decision is expected by November 2023.

Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review

TAMPA, Fla., March 27, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) today announced that the United States Court of Appeals for the Third Circuit affirmed the District Court's dismissal of the Company's suit against the American Society of Anesthesiologists (ASA) and various other defendants.

Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit

TAMPA, Fla., March 22, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that after serving as an independent director for nine years, Yvonne Greenstreet, MBChB, is retiring from the company's Board of Directors effective March 31, 2023. Dr. Greenstreet is currently serving as Chief Executive Officer of Alnylam Pharmaceuticals, Inc. Pacira is initiating a process to identify an independent Board member to replace Dr. Greenstreet.

Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors

TAMPA, Fla., March 08, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 9:00 AM ET on Wednesday, March 15, 2023 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference

Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark.

Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall

Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive Officer Roy Winston - Chief Medical Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants David Amsellem - Piper Sandler Glen Santangelo - Jefferies Gregory Renza - RBC Capital Markets Oren Livnat - H.C. Wainwright Andreas Argyrides - Wedbush Greg Fraser - Truist Securities Operator Good day and thank you for standing by.

Pacira BioSciences, Inc. (PCRX) Q4 2022 Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of 0% and 1.24%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Matches Q4 Earnings Estimates

— Record revenues of $667 million in 2022 —

Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results

TAMPA, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2022 financial results before the open of the U.S. markets on Tuesday, February 28, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Pacira to Report 2022 Financial Results on Tuesday February 28, 2023

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Pacira (PCRX) to Report a Decline in Earnings: What to Look Out for

EXPAREL average daily sales 104% of the prior year for the fourth quarter and 107% of the prior year for the month of December EXPAREL average daily sales 104% of the prior year for the fourth quarter and 107% of the prior year for the month of December

Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million

The heavy selling pressure might have exhausted for Pacira (PCRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

After Plunging -17.19% in 4 Weeks, Here's Why the Trend Might Reverse for Pacira (PCRX)

Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Pacira (PCRX)

Pacira (PCRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Pacira (PCRX) Loses -17.27% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

TAMPA, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference at 3:00 PM PT (6:00PM EST) on Monday, January 9, 2023. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Galapagos

Vir Biotechnology

Here we present three drug and biotech stocks, VIR, GLPG and PCRX, which took a beating in 2022 but have upside potential for 2023, despite an uncertain macro environment.

3 Beaten-Down Drug Stocks Poised for a Turnaround in 2023

Pacira (PCRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Pacira (PCRX) Rating Upgrade to Buy

After losing some value lately, a hammer chart pattern has been formed for Pacira (PCRX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why Pacira (PCRX) Could be Great Choice for a Bottom Fisher

Pacira's (PCRX) flagship product Exparel, along with other marketed products, is driving year over year growth. Pacira's efforts to expand Exparel label also holds promise.

Will Pacira's (PCRX) Exparel Aid Growth Amid High Reliance?

-- EXPAREL average daily sales for October 2022 were 106 percent of October 2021 -- TAMPA, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales of $54.9 million for the month of October 2022. The company's net product sales include EXPAREL® (bupivacaine liposome injectable suspension), ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), and the iovera° system. The company began recognizing sales of ZILRETTA in November 2021 after completing its acquisition of Flexion Therapeutics, Inc.

Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022

TAMPA, Fla., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the following two healthcare conferences:

Pacira BioSciences to Present at Two Healthcare Conferences in November

Pacira's (PCRX) earnings fall shy of estimates in the third quarter of 2022 while revenues beat the same.

Pacira's (PCRX) Q3 Earnings Miss Estimates, Revenues Beat

Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack - Chairman & Chief Executive Officer Roy Winston - Chief Medical Officer Charlie Reinhart - Chief Financial Officer Conference Call Participants Gregory Renza - RBC Capital Markets Serge Belanger - Needham Gary Nachman - BMO Capital Markets Susan Mesco Good morning everyone. Welcome to today's conference call to discuss our Third Quarter 2022 Financial Results.

Pacira BioSciences, Inc. (PCRX) Q3 2022 Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of -12.33% and 0.10%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Pacira Pharmaceuticals Stock (PCRX)